Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00472056 · ClinicalTrials.gov registry record · Phase 2

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

A Phase 2 study, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
93
Enrollment target

NCT00472056: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.

NCT00472056 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 93 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00472056, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
93 participants
Enrollment target

Study Summary

Cohort 1: Patients who are less than or equal to 65 years of age. 1\. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose rituximab) Cohort 2: Patients who are older than 65 years of age 1. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose rituximab) 2. To determine the treatment related mortality (TRM)

Primary Outcome

DFS defined as time from transplantation to disease relapse, disease progression, death during remission, or last follow-up. Evaluation at 3 months and 6 months after transplantation, then every 6 months for 3 years, and then once a year up to 5 years from the transplant date.

Interventions

  • DRUG Melphalan
  • DRUG Rituximab
  • DRUG Etoposide
  • DRUG Cytarabine
  • DRUG Carmustine

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2005-03
Est. Completion 2012-06
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT00472056 record still lists

NCT00472056 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower).

The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.

NCT00472056 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00472056 about?

NCT00472056 is a clinical study titled "Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies". Cohort 1: Patients who are less than or equal to 65 years of age. 1\. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose rituximab) Cohort 2: Patients who are older than 65 years of age 1. To determine the disease-free survival (DFS) in the 2 arms (standard...

What is the current status of trial NCT00472056?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2005-03. Estimated completion is 2012-06.

What interventions are being tested in trial NCT00472056?

The interventions under investigation include: Melphalan (DRUG), Rituximab (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Carmustine (DRUG).

Who is sponsoring clinical trial NCT00472056?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT00472056's enrollment target sits among peer trials

93 766th of 2000 higher than 1,234 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02203526 · 93 participants · Phase 1

    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  • NCT03089554 · 93 participants · Phase 2

    Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

  • NCT05000021 · 93 participants · NA

    Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

  • NCT05489887 · 93 participants · Phase 2

    Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00472056, the US trial registry maintained by the National Library of Medicine. NCT00472056 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.